{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T15:26:26Z","timestamp":1788276386006,"version":"build-2803163510"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":61,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Col. Daniel Connelly Memorial Fund"},{"name":"Andrew Sabin Family Fellowship Award"},{"name":"National Cancer Institute Cancer Center Support Grant","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RR180035"],"award-info":[{"award-number":["RR180035"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Appendiceal Cancer Pseudomyxoma Peritonei Research Foundation"},{"name":"Conquer Cancer Career Development Award","award":["2022CDA-7604125121"],"award-info":[{"award-number":["2022CDA-7604125121"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-026-01817-3","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T07:26:51Z","timestamp":1782977211000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["KRAS inhibition is an effective therapy for appendiceal adenocarcinoma"],"prefix":"10.1186","volume":"19","author":[{"given":"Saikat","family":"Chowdhury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiaki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay K.","family":"Pattalachinti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelrahman M. G.","family":"Yousef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud M. G.","family":"Yousef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sacha","family":"El Khoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Hornstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashlee Nichole","family":"Seldomridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micheal J.","family":"Overman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa W.","family":"Taggart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wai Chin","family":"Foo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Helmink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith F.","family":"Fournier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Paul","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"1817_CR1","first-page":"1","volume":"2","author":"CS-P Ang","year":"2018","unstructured":"Ang CS-P, et al. Genomic Landscape of Appendiceal Neoplasms. JCO Precision Oncol. 2018;2:1\u201318.","journal-title":"JCO Precision Oncol"},{"key":"1817_CR2","doi-asserted-by":"publisher","first-page":"e2316161","DOI":"10.1001\/jamanetworkopen.2023.16161","volume":"6","author":"JP Shen","year":"2023","unstructured":"Shen JP, et al. Efficacy of Systemic Chemotherapy in Patients With Low-grade Mucinous Appendiceal Adenocarcinoma: A Randomized Crossover Trial. JAMA Netw Open. 2023;6:e2316161\u20132316161.","journal-title":"JAMA Netw Open"},{"key":"1817_CR3","doi-asserted-by":"publisher","first-page":"e2316161","DOI":"10.1001\/jamanetworkopen.2023.16161","volume":"6","author":"JP Shen","year":"2023","unstructured":"Shen JP, et al. Efficacy of Systemic Chemotherapy in Patients With Low-grade Mucinous Appendiceal Adenocarcinoma: A Randomized Crossover Trial. JAMA Netw Open. 2023;6:e2316161.","journal-title":"JAMA Netw Open"},{"key":"1817_CR4","doi-asserted-by":"publisher","first-page":"175883592211124","DOI":"10.1177\/17588359221112478","volume":"14","author":"MC Strach","year":"2022","unstructured":"Strach MC, Sutherland S, Horvath LG, Mahon K. The role of chemotherapy in the treatment of advanced appendiceal cancers: summary of the literature and future directions. Ther Adv Med Oncol. 2022;14:17588359221112478.","journal-title":"Ther Adv Med Oncol"},{"key":"1817_CR5","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1200\/JCO.22.01392","volume":"41","author":"MB Foote","year":"2023","unstructured":"Foote MB, et al. Molecular Classification of Appendiceal Adenocarcinoma. J Clin oncology: official J Am Soc Clin Oncol. 2023;41:1553\u201364.","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"key":"1817_CR6","first-page":"762","volume":"22","author":"N Khan","year":"2025","unstructured":"Khan N, et al. Drugging the \u2018undruggable\u2019KRAS: breakthroughs, challenges, and opportunities in pancreatic cancer. Cancer Biology Med. 2025;22:762\u201388.","journal-title":"Cancer Biology Med"},{"key":"1817_CR7","doi-asserted-by":"publisher","first-page":"e247067","DOI":"10.6004\/jnccn.2024.7067","volume":"23","author":"DA Deming","year":"2025","unstructured":"Deming DA. Development of KRAS Inhibitors and Their Role for Metastatic Colorectal Cancer. J Natl Compr Canc Netw. 2025;23:e247067.","journal-title":"J Natl Compr Canc Netw"},{"key":"1817_CR8","unstructured":"Benson AB, Venook AP, Adam M. NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. Version 5.2024."},{"key":"1817_CR9","unstructured":"Benson AB, Venook AP, Adam M. NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer. Version 4.2024."},{"key":"1817_CR10","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1056\/NEJMoa2303810","volume":"389","author":"A Sacher","year":"2023","unstructured":"Sacher A, et al. Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation. N Engl J Med. 2023;389:710\u201321.","journal-title":"N Engl J Med"},{"key":"1817_CR11","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1200\/JCO.2024.42.16_suppl.3007","volume":"42","author":"RS Heist","year":"2024","unstructured":"Heist RS, et al. Pan-tumor activity of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in patients with <\u2009i>KRAS G12C-mutant advanced solid tumors. J Clin Oncol. 2024;42:3007\u20133007.","journal-title":"J Clin Oncol"},{"key":"1817_CR12","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1021\/acs.jmedchem.1c01688","volume":"65","author":"X Wang","year":"2022","unstructured":"Wang X, et al. Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS(G12D) Inhibitor. J Med Chem. 2022;65:3123\u201333.","journal-title":"J Med Chem"},{"key":"1817_CR13","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1158\/1078-0432.CCR-23-2098","volume":"30","author":"D Wei","year":"2024","unstructured":"Wei D, Wang L, Zuo X, Maitra A, Bresalier RS. A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer. Clin Cancer Res. 2024;30:655\u201362.","journal-title":"Clin Cancer Res"},{"key":"1817_CR14","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.trecan.2023.07.010","volume":"9","author":"MN Zeissig","year":"2023","unstructured":"Zeissig MN, Ashwood LM, Kondrashova O, Sutherland KD. Next batter up! Targeting cancers with KRAS-G12D mutations. Trends Cancer. 2023;9:955\u201367.","journal-title":"Trends Cancer"},{"key":"1817_CR15","doi-asserted-by":"publisher","unstructured":"Tedeschi A et al. Pan-KRAS inhibitors BI-2493 and BI-2865 display potent anti-tumor activity in tumors with KRAS wild-type allele amplification. Mol Cancer Ther. 2024;24(4):550\u201362. https:\/\/doi.org\/10.1158\/1535-7163.mct-24-0386.","DOI":"10.1158\/1535-7163.mct-24-0386"},{"key":"1817_CR16","doi-asserted-by":"publisher","first-page":"104250","DOI":"10.1016\/j.drudis.2024.104250","volume":"30","author":"P Filis","year":"2024","unstructured":"Filis P, Salgkamis D, Matikas A, Zerdes I. Breakthrough in RAS targeting with pan-RAS(ON) inhibitors RMC-7977 and RMC-6236. Drug Discov Today. 2024;30:104250.","journal-title":"Drug Discov Today"},{"key":"1817_CR17","doi-asserted-by":"publisher","unstructured":"Nusrat F et al. The Clinical Implications of KRAS Mutations and Variant Allele Frequencies in Pancreatic Ductal Adenocarcinoma. J Clin Med. 2024;13(7):2103. https:\/\/doi.org\/10.3390\/jcm13072103.","DOI":"10.3390\/jcm13072103"},{"key":"1817_CR18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2208470","volume":"388","author":"JH Strickler","year":"2023","unstructured":"Strickler JH, et al. Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer. N Engl J Med. 2023;388:33\u201343.","journal-title":"N Engl J Med"},{"key":"1817_CR19","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1200\/JCO.23.00434","volume":"41","author":"TS Bekaii-Saab","year":"2023","unstructured":"Bekaii-Saab TS, et al. Adagrasib in Advanced Solid Tumors Harboring a KRAS(G12C) Mutation. J Clin oncology: official J Am Soc Clin Oncol. 2023;41:4097\u2013106.","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"key":"1817_CR20","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1158\/2159-8290.CD-24-0027","volume":"14","author":"J Jiang","year":"2024","unstructured":"Jiang J, et al. Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers. Cancer Discov. 2024;14:994\u20131017.","journal-title":"Cancer Discov"},{"key":"1817_CR21","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1038\/s41388-023-02676-9","volume":"42","author":"J Feng","year":"2023","unstructured":"Feng J, et al. Feedback activation of EGFR\/wild-type RAS signaling axis limits KRAS(G12D) inhibitor efficacy in KRAS(G12D)-mutated colorectal cancer. Oncogene. 2023;42:1620\u201333.","journal-title":"Oncogene"},{"key":"1817_CR22","doi-asserted-by":"publisher","first-page":"eadk0775","DOI":"10.1126\/science.adk0775","volume":"384","author":"JA Klomp","year":"2024","unstructured":"Klomp JA, et al. Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers. Science. 2024;384:eadk0775.","journal-title":"Science"},{"key":"1817_CR23","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41586-023-05915-x","volume":"619","author":"JW Hickey","year":"2023","unstructured":"Hickey JW, et al. Organization of the human intestine at single-cell resolution. Nature. 2023;619:572\u201384.","journal-title":"Nature"},{"key":"1817_CR24","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1093\/carcin\/bgu157","volume":"35","author":"JR Wang","year":"2014","unstructured":"Wang JR, et al. Orphan nuclear receptor Nur77 promotes colorectal cancer invasion and metastasis by regulating MMP-9 and E-cadherin. Carcinogenesis. 2014;35:2474\u201384.","journal-title":"Carcinogenesis"},{"key":"1817_CR25","doi-asserted-by":"publisher","first-page":"e22609","DOI":"10.1096\/fj.202101817RR","volume":"36","author":"HE Szczepanski","year":"2022","unstructured":"Szczepanski HE, et al. NR4A1 modulates intestinal smooth muscle cell phenotype and dampens inflammation-associated intestinal remodeling. FASEB J. 2022;36:e22609.","journal-title":"FASEB J"},{"key":"1817_CR26","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41420-024-01886-8","volume":"10","author":"S Polo-Generelo","year":"2024","unstructured":"Polo-Generelo S, et al. Serpine1 mRNA confers mesenchymal characteristics to the cell and promotes CD8\u2009+\u2009T cells exclusion from colon adenocarcinomas. Cell Death Discovery. 2024;10:116.","journal-title":"Cell Death Discovery"},{"key":"1817_CR27","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1093\/cvr\/cvad016","volume":"119","author":"K van Kuijk","year":"2023","unstructured":"van Kuijk K, et al. Human and murine fibroblast single-cell transcriptomics reveals fibroblast clusters are differentially affected by ageing and serum cholesterol. Cardiovasc Res. 2023;119:1509\u201323.","journal-title":"Cardiovasc Res"},{"key":"1817_CR28","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.ccell.2023.02.015","volume":"41","author":"G Caligiuri","year":"2023","unstructured":"Caligiuri G, Tuveson DA. Activated fibroblasts in cancer: Perspectives and challenges. Cancer Cell. 2023;41:434\u201349.","journal-title":"Cancer Cell"},{"key":"1817_CR29","doi-asserted-by":"publisher","first-page":"4061","DOI":"10.1038\/s41467-020-17883-1","volume":"11","author":"DS Foster","year":"2020","unstructured":"Foster DS, et al. Elucidating the fundamental fibrotic processes driving abdominal adhesion formation. Nat Commun. 2020;11:4061.","journal-title":"Nat Commun"},{"key":"1817_CR30","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1016\/j.ccell.2024.08.020","volume":"42","author":"Y Gao","year":"2024","unstructured":"Gao Y, et al. Cross-tissue human fibroblast atlas reveals myofibroblast subtypes with distinct roles in immune modulation. Cancer Cell. 2024;42:1764\u2013e17831710.","journal-title":"Cancer Cell"},{"key":"1817_CR31","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1186\/s12885-025-14261-2","volume":"25","author":"S Zhao","year":"2025","unstructured":"Zhao S, et al. INHBA(+) macrophages and Pro-inflammatory CAFs are associated with distinctive immunosuppressive tumor microenvironment in submucous Fibrosis-Derived oral squamous cell carcinoma. BMC Cancer. 2025;25:857.","journal-title":"BMC Cancer"},{"key":"1817_CR32","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/s41401-024-01381-x","volume":"46","author":"F-l Li","year":"2025","unstructured":"Li F-l, et al. INHBA promotes tumor growth and induces resistance to PD-L1 blockade by suppressing IFN-\u03b3 signaling. Acta Pharmacol Sin. 2025;46:448\u201361.","journal-title":"Acta Pharmacol Sin"},{"key":"1817_CR33","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/s41374-019-0345-3","volume":"100","author":"X Zhang","year":"2020","unstructured":"Zhang X, et al. CCL8 secreted by tumor-associated macrophages promotes invasion and stemness of glioblastoma cells via ERK1\/2 signaling. Lab Invest. 2020;100:619\u201329.","journal-title":"Lab Invest"},{"key":"1817_CR34","doi-asserted-by":"publisher","first-page":"13255","DOI":"10.1038\/s41598-020-69899-8","volume":"10","author":"L-C Cheng","year":"2020","unstructured":"Cheng L-C, et al. Increased expression of secreted frizzled related protein 1 (SFRP1) predicts ampullary adenocarcinoma recurrence. Sci Rep. 2020;10:13255.","journal-title":"Sci Rep"},{"key":"1817_CR35","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1634\/theoncologist.2014-0415","volume":"20","author":"MJ Overman","year":"2015","unstructured":"Overman MJ, et al. Challenges of efficacy assessments in pseudomyxoma peritonea. Oncologist. 2015;20:e3\u20134.","journal-title":"Oncologist"},{"key":"1817_CR36","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","volume":"21","author":"GJ Rustin","year":"2011","unstructured":"Rustin GJ, et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer. 2011;21:419\u201323.","journal-title":"Int J Gynecol Cancer"},{"key":"1817_CR37","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41698-025-00821-z","volume":"9","author":"VK Pattalachinti","year":"2025","unstructured":"Pattalachinti VK, et al. BRAF mutant appendiceal adenocarcinoma differs from colorectal cancer but responds to BRAF-targeted therapy. npj Precision Oncol. 2025;9:38.","journal-title":"npj Precision Oncol"},{"key":"1817_CR38","doi-asserted-by":"publisher","first-page":"4082","DOI":"10.1158\/1078-0432.CCR-23-4072","volume":"30","author":"J Mart\u00ednez-Quintanilla","year":"2024","unstructured":"Mart\u00ednez-Quintanilla J, et al. Precision Oncology and Systemic Targeted Therapy in Pseudomyxoma Peritonei. Clin Cancer Res. 2024;30:4082\u201399.","journal-title":"Clin Cancer Res"},{"key":"1817_CR39","doi-asserted-by":"publisher","first-page":"4112","DOI":"10.1158\/0008-5472.CAN-23-2994","volume":"83","author":"AC Edwards","year":"2023","unstructured":"Edwards AC, et al. Inhibition Overcomes YAP1\/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors. Cancer Res. 2023;83:4112\u201329.","journal-title":"Cancer Res"},{"key":"1817_CR40","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1158\/2159-8290.CD-24-0489","volume":"15","author":"Y Liu","year":"2025","unstructured":"Liu Y, et al. Inhibition and Immune Therapy Generates Durable Complete Responses in an Autochthonous PDAC Model. Cancer Discov. 2025;15:162\u201378. Combined KRAS.","journal-title":"Cancer Discov"},{"key":"1817_CR41","doi-asserted-by":"publisher","first-page":"5012","DOI":"10.1158\/1078-0432.CCR-22-3655","volume":"29","author":"J Boumelha","year":"2023","unstructured":"Boumelha J, Molina-Arcas M, Downward J. Facts and hopes on RAS inhibitors and cancer immunotherapy. Clin Cancer Res. 2023;29:5012\u201320.","journal-title":"Clin Cancer Res"},{"key":"1817_CR42","unstructured":"Gunes BB et al. (American Society of Clinical Oncology, 2024)."},{"key":"1817_CR43","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1158\/2767-9764.CRC-24-0019","volume":"4","author":"NJ Hornstein","year":"2024","unstructured":"Hornstein NJ, et al. Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma. Cancer Res Commun. 2024;4:1363\u20138.","journal-title":"Cancer Res Commun"},{"key":"1817_CR44","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","volume":"21","author":"GJS Rustin","year":"2011","unstructured":"Rustin GJS, et al. Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer. 2011;21:419\u201323.","journal-title":"Int J Gynecol Cancer"},{"key":"1817_CR45","doi-asserted-by":"publisher","unstructured":"Roensholdt S, Detlefsen S, Mortensen MB, Graversen M. Response Evaluation in Patients with Peritoneal Metastasis Treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC). J Clin Med. 2023;12(4):1289. https:\/\/doi.org\/10.3390\/jcm12041289.","DOI":"10.3390\/jcm12041289"},{"key":"1817_CR46","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1056\/NEJMoa2505783","volume":"394","author":"BM Wolpin","year":"2026","unstructured":"Wolpin BM, et al. Daraxonrasib in Previously Treated Advanced\u2009<\u2009i>RAS-Mutated Pancreatic Cancer. N Engl J Med. 2026;394:1790\u2013802.","journal-title":"N Engl J Med"},{"key":"1817_CR47","doi-asserted-by":"publisher","unstructured":"Ito I et al. Development and characterization of orthotopic patient-derived xenograft models of peritoneal metastatic mucinous appendiceal adenocarcinoma. ESMO Gastrointest Oncol. 2025;7:C. https:\/\/doi.org\/10.1016\/j.esmogo.2025.100133.","DOI":"10.1016\/j.esmogo.2025.100133"},{"key":"1817_CR48","doi-asserted-by":"publisher","first-page":"e240260","DOI":"10.1001\/jamanetworkopen.2024.0260","volume":"7","author":"A Yousef","year":"2024","unstructured":"Yousef A, et al. Serum Tumor Markers and Outcomes in Patients With Appendiceal Adenocarcinoma. JAMA Netw Open. 2024;7:e240260\u2013240260.","journal-title":"JAMA Netw Open"},{"key":"1817_CR49","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1158\/1078-0432.CCR-24-2474","volume":"31","author":"MG White","year":"2025","unstructured":"White MG, et al. The Landscape of ctDNA in Appendiceal Adenocarcinoma. Clin Cancer Res. 2025;31:551\u201360.","journal-title":"Clin Cancer Res"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-026-01817-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01817-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01817-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T15:06:56Z","timestamp":1788275216000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13045-026-01817-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1817"],"URL":"https:\/\/doi.org\/10.1186\/s13045-026-01817-3","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"assertion":[{"value":"27 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Patient data were retrospectively collected under the guidance of an IRB-approved study with an informed consent waiver approved by the University of Texas MD Anderson Cancer Center. All animal studies were performed according to protocols approved by the Institutional Animal Care and Use Committee of MD Anderson Cancer Center and conducted in accordance with U.S. Common Rule.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. John Paul Shen: Grant\/Research support\/ Collaboration: Natera, Inc; BostonGene; Revolution Medicine; Summit TherapeuticsConsulting \/ Stock ownership: Engine Biosciences, NaDeNo NanosciencePatent: Siegel D, Schweer J, Abagyan R, Shen JP. SMALL MOLECULE FOR TREATMENT OF CANCER OF THE APPENDIX. Filed July 17, 2023, PCT\/US2023\/027939Dr. David Hong: Grant\/Research support\/ Collaboration: 280 Bio, AbbVie, Adaptimmune, Adlai-Nortye, Amgen, Astelles, Astra-Zeneca, Bayer, BeiGene USA, BioBridge, Biomea Fusion, Bristol-Myers Squibb, Deciphera, E.R. Squibb & Sons LLC, Eisai, Eli Lilly, Endeavor, Erasca, Exelixis Inc., F. Hoffmann-LaRoche, Genentech, Immunogenesis, Incyte Inc., Merck, Mirati, NCI-CTEP, Novartis, Pfizer, Quanta Therapeutics, Revolution Medicines, STCube Pharmaceuticals, VM Oncology, and Yiling Pharmaceutical. Travel, accommodations, or expense support: American Association of Cancer Research (AACR), American Society of Clinical Oncology (ASCO), Bayer, BeiGene USA Inc., Genmab, Medscape, Mirati Therapeutics Inc., Pfizer, Society for the Immunotherapy of Cancer (SITC), and Telperian. Consulting, speaker, or advisory role: 280 Bio, Acuta Capital Partners LLC, Alpha Insights, Amgen, Bayer, Boxer Capital, Children\u2019s Oncology Group, COR2ed, Cowen Group Inc, Crossbridge Bio, Ecor1 Capital, Erasca, Gerson Lehrman Group Inc., Group H, Guidepoint, Immunogenesis, Jansen Pharmaceuticals, Kestrel Therapeutics, Medacorp, Medscape, Orbi Capital, Pfizer, Revolution Medicines, T-Knife, Travistock Group, WebMD, and Yiling Pharmaceutical. Ownership interests: Molecular Match (Advisor), OncoResponse (Founder, Advisor), Telperian (Founder, Advisor), and CrossBridge Bio (Advisor).Dr. Michael J. Overman: Consulting\/advisory role: Bristol Myers Squibb, Roche\/Genentech, Gritstone Bio, MedImmune, Novartis, Array BioPharma, Janssen, Pfizer, 3D Medicines, Merck, Eisai, Simcere; Research funding: Bristol Myers Squibb, Merck, Roche, MedImmune.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"70"}}